WLWT: UC hosts RESET epilepsy trial
WLWT recently highlighted the RESET study, a trial at the University of Cincinnati that will study a new treatment for the most severe and deadly form of epilepsy.
Brandon Foreman, MD, site principal investigator at UC for the trial being conducted across approximately 50 hospital emergency departments across the country, told WLWT the study focuses on a condition called status epilepticus (SE).
"About 10 percent of the folks who have seizures, when they come into the emergency department, are having status epilepticus," said Foreman, associate professor and associate director of neurocritical care research in the Department of Neurology and Rehabilitation Medicine in UC’s College of Medicine and a UC Health physician. SE is a disorder Foreman described as "seizures that don't stop."
The trial will test a new drug, ganaxolone, a neurosteroid your brain produces that can help stop seizures that won't end on their own.
"So, the promise with this medication is if you're still having seizures, despite that kind of class, one level of evidence medication...that we can give this medication and it sort of fits in at that point. Hopefully, we'll stop the seizures," Foreman said.
Featured photo at top of ambulance. Photo/Camilo Jimenez/Unsplash.
Related Stories
‘Designer drug’ shows early neuroprotective signal in acute ischemic stroke
October 28, 2025
Medscape highlighted new trial results led by the University of Cincinnati's Eva Mistry that found an experimental drug shows promise in protecting injured brain cells for patients with acute ischemic stroke.
UC Board votes to fund design for YMCA renovation
October 28, 2025
At its October 28, 2025 meeting, the University of Cincinnati Board of Trustees approved $5 million in funding to complete all design and pre-construction services required to renovate the interior of a former YMCA building located at 270 Calhoun Street.
Is menstrual fluid ‘the most overlooked opportunity’ in women’s health?
October 27, 2025
The Guardian recently reported that period blood has long been thought of as ‘stinky and useless’, but startups are exploring using the fluid to test for a wide range of health conditions — including endometriosis.